Skip to main content

Table 1 Clinical characteristics in the study population

From: Effect of 1,5-anhydroglucitol levels on culprit plaque rupture in diabetic patients with acute coronary syndrome

VariablesRuptureNon-ruptureP value
n4995 
Age (years)59 ± 960 ± 100.474
Males28 (57.1)62 (65.3)0.340
Current smoking34 (69.4)51 (53.7)0.069
Hypertension36 (73.5)65 (68.4)0.531
Hyperlipidemia32 (65.3)58 (61.1)0.617
Duration of diabetes (years)4.2 (2.0, 5.2)2.5 (1.2, 4.8)0.009
BMI (kg/m2)26.4 ± 3.625.6 ± 3.50.110
LVEF (%)59.5 ± 8.362.2 ± 9.20.092
eGFR (mL/min/1.73 m2)84.6 ± 28.688.0 ± 30.80.491
SBP (mmHg)130 ± 13131 ± 160.612
DBP (mmHg)76 ± 877 ± 100.638
TG (mmol/L)1.93 (1.12, 2.13)1.72 (0.94, 1.88)0.079
HDL-C (mmol/L)0.96 (0.82, 1.24)1.02 (0.91, 1.23)0.314
Non-HDL-C (mmol/L)4.39 (3.63, 4.99)3.83 (3.43, 4.36)0.006
WBC (109/L)7.3 ± 1.67.2 ± 1.70.958
hs-CRP (mg/dL)2.46 (1.61, 5.23)1.22 (0.84, 4.01)0.014
NT-proBNP390 (155, 960)362 (105, 890)0.413
TnI1.20 (0.11, 5.12)0.91 (0.03, 2.62)0.228
Urinary 8-iso-PGF (pmol/mmolCr)141.9 ± 67.2116.1 ± 71.60.038
FBG (mmol/L)8.1 ± 3.07.1 ± 2.00.023
HbA1c (%)7.2 ± 0.57.0 ± 0.60.025
1,5-AG (µg/mL)10.5 ± 5.514.1 ± 7.70.005
Medications on admission   
 Aspirin36 (73.5)71 (74.7)0.869
 Statins27 (55.1)62 (65.3)0.234
 ACEI/ARB25 (51.0)52 (54.7)0.672
 Oral antidiabetic drugs31 (63.3)64 (67.4)0.622
 Insulin16 (32.7)32 (33.7)0.901
  1. Data are given as number (percentage) for categorical variables and mean ± standard deviation or median (IQR) for continuous variables
  2. BMI body mass index, LVEF left ventricular ejection fraction, eGFR estimated glomerular filtration rate, SBP systolic blood pressure, DBP diastolic blood pressure, TG triglycerides, HDL-C high-density lipoprotein cholesterol, non-HDL-C non-high-density lipoprotein cholesterol, WBC white blood cell, hs-CRP high-sensitivity C-reactive protein, NT-proBNP N-terminal pro-brain natriuretic peptide, TnI troponin I, 8-iso-PGF 8-iso-prostaglandin F, FBG fasting blood glucose, HbA1c hemoglobin A1c, 1,5-AG 1,5-anhydroglucitol, ACEI/ARB angiotensin-converting-enzyme inhibitor/angiotensin II receptor blocker